Biotechnology Acquisitions in Michigan
Showing 5 transactions.
-
January 5, 2025
- Buyer
- NanoImaging Services, Ampersand Capital Partners
- Target
- Proteos, Inc.
- Industry
- Biotechnology
- Location
- Michigan, United States
- Type
- Addon
NanoImaging Services (NIS), a cryo-electron microscopy services provider backed by Ampersand Capital Partners, has acquired Proteos, Inc., a Kalamazoo-based CRO specializing in recombinant protein and antibody production. The add-on acquisition integrates Proteos’ protein production capabilities with NIS’s cryo-EM services to create an end-to-end offering for structure-based drug discovery and protein production workflows.
-
March 11, 2021
- Buyer
- Integrated DNA Technologies (IDT)
- Target
- Swift Biosciences
- Industry
- Biotechnology
- Location
- Michigan, United States
- Type
- Buyout
Integrated DNA Technologies (IDT) has acquired Swift Biosciences, a developer of Next-Generation Sequencing (NGS) library preparation and enrichment kits. The acquisition brings Swift's library prep and enrichment portfolio and Ann Arbor-based team into IDT to expand IDT's NGS product offerings and accelerate growth in academic, translational, and clinical research markets. Financial terms were not disclosed.
-
May 26, 2020
- Buyer
- Shionogi & Co., Ltd.
- Target
- Tetra Therapeutics
- Industry
- Biotechnology
- Location
- Michigan, United States
- Type
- Buyout
Shionogi & Co., Ltd. agreed to acquire clinical-stage biopharmaceutical company Tetra Therapeutics, giving Shionogi global rights to Tetra's portfolio including BPN14770. The deal, announced May 26, 2020, is valued at up to $500 million in milestone and contingent payments.
-
April 9, 2020
- Buyer
- Bio-Rad Laboratories, Inc.
- Target
- Celsee, Inc.
- Industry
- Biotechnology
- Location
- Michigan, United States
- Type
- Buyout
Bio-Rad Laboratories has acquired Celsee, Inc., a developer of instruments and consumables for single-cell isolation, detection and analysis. The acquisition expands Bio‑Rad’s capabilities in single-cell analysis and precision medicine; terms were not disclosed.
-
January 8, 2020
- Buyer
- StemBioSys, Inc.
- Target
- CARTOX, Inc.
- Industry
- Biotechnology
- Location
- Michigan, United States
- Type
- Buyout
San Antonio-based StemBioSys acquired a majority stake in Ann Arbor startup Cartox, obtaining control with plans to purchase the remaining equity subject to milestones. The deal brings Cartox's cardiotoxicity imaging and assay capabilities together with StemBioSys's CELLvo extracellular matrix technology to accelerate commercial development of pre-clinical cardiac safety and efficacy screening solutions.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.